Sep 2026
Design and Synthesis of Novel TLR2 Agonists for Regulating Tumor Microenvironment in Immunotherapy of Lung Cancer.
Overall, SMU-H1 retains robust TLR2 agonistic activity with reduced toxicity, representing a promising candidate for cancer immunotherapy development.
Yue Pan, Qiu-Yue Fu, Zhuo-Xian Cao et al.
· Journal of Medicinal Chemist... · 0 citations